[Ip-health] Syncopation Life Sciences

James Love james.love at keionline.org
Fri Jul 9 05:44:51 PDT 2021


Syncopatiion Life Sciences is seeking an exclusive worldwide NIH license to
a portfolio of patents on Monospecific CD22 Chimeric Antigen Receptor (CAR)
Therapies for the Treatment of B-Cell Malignancies.

The company was incorporated in Palo Alto in May.  Financial backers
include Samsara BioCapital.  Three listed founders include Nancy Goodman,
better known to some for her charity, https://www.kidsvcancer.org/, and her
role in lobbying for the pediatric priority review voucher.  She is married
to Michael Froman, the former head of USTR under Obama.  The other two
founders are two Stanford scientists, the well known Crystal Mackall, and
Robbie Majzner.  Mackall is listed as the principal investigator in $52
million of NIH/NCI grants.

Given the vast global inequality in access to cell therapies, we are asking
the NIH to limit the exclusivity to countries with per capita incomes of at
least 30 percent of the U.S.  We are also making other requests for public
interest safeguards that, under Dr. Collins' leadership, the NIH has
consistently rejected, on topics such as transparency and affordable
pricing.

https://www.federalregister.gov/documents/2021/06/24/2021-13260/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-monospecific
"This technology discloses CAR therapies that target CD22 by utilizing the
anti-CD22 binder known as m971. CD22 is expressed on the surface of B cells
in B cell malignancies and CD22-targeting CAR-T has shown early promise in
clinical trials for ALL and NHL."


https://syncopationlife.com/#about


NANCY GOODMAN JD
Founder
Nancy Goodman is the CEO of Kids v Cancer, a nonprofit dedicated to policy
reform to attract biotech and pharmaceutical companies to pediatric cancer
drug development. Ms. Goodman is an author and the lead advocate of the
RACE for Children Act, which was passed into U.S. law in 2017 (21 U.S.C.
355c). The RACE for Children Act amends the Pediatric Research Equity Act
to authorize the FDA to require companies developing cancer targeted
therapies to undertake pediatric studies when the molecular targets of the
drugs in development are substantially relevant to pediatric cancer
indications. She is also the author and lead advocate of the Creating Hope
Act Rare Pediatric Priority Review Voucher Program, passed into U.S. law in
2012 (21 U.S.C. 360ff). The priority review voucher program establishes a
market-based incentive, a voucher, for companies to develop drugs expressly
for children with cancer and other life-threatening illnesses. Over $1.2
billion in vouchers have been traded since the establishment of the
program. In 2015, Kids v Cancer under Ms Goodman’s leadership launched a
Compassionate Use Navigator for pediatric cancer patients. In 2010, Kids v
Cancer launched a post mortem pediatric brain tumor tissue donation program
under Ms. Goodman’s leadership.  Among the honors she has received are:
American Association of Cancer Research Distinguished Advocacy Award, Fast
Company Magazine as top ten most innovative nonprofits (award to Kids v
Cancer), US Food and Drug Administration Group Recognition Award, Member of
U.S. Vice President’ Biden’s Blue Ribbon Pediatric Oncology Panel for the
Cancer Moonshot, Member of National Cancer Institute Board of Scientific
Counselors.


More information about the Ip-health mailing list